argenx (ENXTBR:ARGX) Following Strong H1 Results Looks Pricey Under The Leading Narrative
argenx (ENXTBR:ARGX) is back in focus after reporting half year 2026 earnings, with revenue of US$2.854b and net income of US$838m, supported by VYVGART and its expanded generalized myasthenia gravis reach.
See our latest analysis for argenx.
argenx's recent half year earnings and VYVGART label expansion have coincided with building momentum, with a 20.74% 90 day share price return and a 59.60% 1 year total shareholder return from a €804.4 share price today.
If you are interested in other immunology and biotech names using AI in drug discovery, it could be worth scanning a wider field through the 128 healthcare AI stocks
After argenx’s strong half year report and a share price that has already run hard, the real tension now is simple: does the current valuation already reflect this momentum, or is there still a margin of safety for new capital?
Most Popular Narrative: 17.2% Overvalued
According to the most followed narrative on argenx, the current share price of €804.4 sits above a narrative fair value of €686.43, creating a valuation gap that investors are watching closely.
argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases. The investment thesis is based on:
• ✅ Leadership in a new therapeutic class (FcRn inhibitors)
• ✅ Very strong commercial growth (revenues doubled in 2 years)
• ✅ Pipeline with multiple near-term catalysts (2026 to 2027)
• ⚠️ Typical biotech risks: dependence on a single asset, pricing pressure, competition
Want to see what sits behind that premium on argenx? The narrative leans on compounded revenue gains, high margins and a future earnings multiple that assumes serious execution. Curious which exact financial assumptions send the fair value below today’s price?
Result: Fair Value of €686.43 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that premium narrative on argenx could be pressured if VYVGART concentration risks materialize, or if late stage trials and regulatory decisions disappoint expectations.
Find out about the key risks to this argenx narrative.
Another View: argenx Through the SWS DCF Lens
While the most followed community narrative sees argenx as 17.2% overvalued at €804.4 versus a €686.43 fair value, the SWS DCF model points in the opposite direction, indicating the stock is trading well below an estimated future cash flow value of €2,469.52. That kind of gap suggests either very cautious market expectations or very optimistic cash flow assumptions. Which side of that spread do you think is closer to reality?
For a clearer sense of how this model works in practice, and which assumptions matter most for argenx, take a closer look at the SWS DCF framework here, then decide how much weight you want to give it beside the narrative fair value, Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out argenx for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 247 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Given the mixed signals around argenx, it makes sense to move quickly from headlines to the underlying data and test how the story holds up for you. To weigh these mixed signals properly and see the full list of concerns alongside the potential upsides, start by reviewing the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond argenx?
If argenx has your attention, do not stop there. Widen your opportunity set with a few targeted screens that surface very different types of stocks.
- Target higher yield potential by reviewing companies described as 458 dividend fortresses and see which payouts currently look most resilient.
- Hunt for mispriced quality by scanning the 247 high quality undervalued stocks and compare fundamentals before committing fresh capital.
- Prioritize resilience by filtering for 295 resilient stocks with low risk scores so you are not missing stocks with steadier risk profiles than argenx.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com